Safety of high-dose nicotinamide: A review

Diabetologia

Volumn 43, Issue 11, 2000, Pages 1337-1345

  Knip, M ^a   Douek, I F ^b   Moore, W P T ^b   Gillmor, H A ^b   McLean, A E M ^c   Bingley, P J ^b   Gale, E A M ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Nicotinamide; Prevention; Type I diabetes

Indexed keywords

ALLOXAN; AMIDE; FOOD ADDITIVE; LIVER ENZYME; NICOTINAMIDE; STREPTOZOCIN; VITAMIN;

ALLOXAN DIABETES MELLITUS; DRUG SAFETY; DRUG SCREENING; GLUCOSE TRANSPORT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STREPTOZOCIN DIABETES;

EID: 0033752240     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051536     Document Type: Review

References (74)

1. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus
2. Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin
3. Nicotinamide in Type 1 Diabetes
4. Water-soluble vitamins. The vitamin B complex and ascorbic acid
5. Niacin revisited: A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolaemia
6. Studies of nicotinic acid use in hypercholesterolaemia
7. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio
8. An evaluation of niacinamide in the treatment of childhhood schizophrenia
9. High-dose nicotinamide in the treatment of necrobiosis lipoidica
10. Megavitamin B-3 therapy for schizophrenia
11. Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients
12. Response of generalized granuloma annulare to high-dose niacinamid
13. Effect of nicotin-amide therapy upon B-cell function in newly-diagnosed Typ I (insulin-dependent) diabetic patients
14. Nicotinamide may extend remission phase in insulin-dependent diabetes
15. Effect of nicotinamide on the residual insulin secretion of Type I (insulin-dependent) diabetic patients
16. Double-blind randomized trial of nicotinamide on early-onset diabetes
17. A trial of nicotinamide in newly diagnosed patients with Type I (insulin-dependent) diabetes mellitus
18. Prevention or delay of Type I (insulin-dependent) diabetes mellitus in children using nicotin-amide
19. A population based strategy to prevent insulin-dependent diabetes using nicotinamide
20. The Deutsche Nicotinamide Intervention Study: An attempt to prevent Type I diabetes
21. Genetic variations of an oxidase in mammals
22. Comparative studies in niacin metabolism. The fate of niacin in man, rat, dog, pig, rabbit, guinea-pig, goat, sheep and calf
23. Pharmacokinetics of nicotinic acid and some of its derivatives
24. The metabolism of high retakes of tryptophan, nicotinamide and nicotinic acid in the rat
25. The inhibition of rat growth by nicotinamide
26. The effect of excessive nicotinamide feeding on rabbits and guinea-pigs
27. The pharmacokinetics of nicotinamide in humans and rodents
28. Measurement of nicotinamide and N-methyl-2-pyridone-5-carboxamide in plasma by high performance liquid chromatography
29. Renal tubular elimination of n-methylnicotinamide
30. High performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine
31. Niacinamide
32. Biochemistry of nicotinic acid and nicotinamide
33. Effects of megavitamin therapy on children with attention deficit disorders
34. Hepatic toxicity from large doses of vitamin B3 (nicotinamide)
35. Clofibrate and niacin in coronary heart disease
36. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study)
37. Certain metabolic effects of niacin and priscoline
38. Diet and cholesteremia IV. Effects of carbohydrate and nicotinic acid
39. Prophylaxis of poisoning by carbon tetrachloride
40. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide
41. Nicotinamide counteracts alcohol-induced impairment of hepatic protein metabolism in humans
42. The effect of nicotinamide and α-ketoglutaric acid on the teratogenic action of insulin
43. Teratogenic and antiteratogenic effects of nicotinamide derivatives in chick embryos
44. Reversal of insulin-induced hypoglycaemia in chick embryos by nicotinamide and α-ketoglutaric acid
45. Problems of acetazolamide and N-ethylnicotinamide as teratogens
46. Pancreatic islet cell tumors produced by the combined action of streptozotocin and nicotinamide
47. Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice
48. Molecular basis of experimental diabetes: Degeneration, oncogenesis and regeneration of B-cells of islets of Langerhans
49. Induction of rat pancreatic B-cell tumours by the combined administration of streptozocin or alloxan and poly (ADP-ribose) synthetase inhibitors
50. Pancreatic islet cell tumours found in rats given alloxan and nicotinamide
51. Tumorigenic action of streptozotocin on the pancreas and kidney in male wistar rats
52. Pilot trial to prevent Type I diabetes: Progression to overt IDDM despite oral nicotinamide
53. Nicotinamide increases C-peptide secretion in patients with recent onset Type I diabetes
54. A preliminary multicentre study of the treatment of recently diagnosed Type I diabetes by combination nicotinamide-cyclosporin therapy
55. Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis
56. Treatment of polymorphous light eruption with nicotinamide: A pilot study
57. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: Further support for its efficacy
58. Effect of D- or L-Methionine and cysteine on the growth inhibitory effects of feeding 1% paracetamol to rats
59. Methylated niacin derivatives in plasma and urine after an oral dose of nicotinamide given to subjects fed a low-methionine diet
60. Effects of nicotin-amide supplementation on human pancreatic islet function in tissue culture
61. Nicotinamide and insulin secretion in normal subjects
62. Nicotinamide and insulin sensitivity
63. Meta-analysis of nicotinamide treatment in patients with recent-onsent IDDM
64. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM
65. Reactions to niacinamide
66. Niacin or niacinamide? Nicotinic acid or nicotinamide? What is the difference?
67. Vitamin B complex, niacin
68. Nicotinic acid, nicotinamide
69. ARCON - Current status: Summary of a workshop on preclinical and clinical studies
70. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type I diabetes (The IMDIAB VI)
71. Measurement of N-methyl-2-pyridone-5-carboxamide in urine by high performance liquid chromatography
72. Hepatic toxicity of unmodified and time-release preparations of niacin
73. Efficacy and safety of an extended-release niacin (niaspan): A long-term study
74. Nicotinamide - Biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992